Pharmaceutical equipment companies are working hard to sprint to the fourth quarter!

【Pharmaceutical Network Industry News】For pharmaceutical equipment companies, the fourth quarter is a key period to complete the annual target tasks, and there is no room for any relaxation
.
Recently, while major enterprises in the pharmaceutical equipment industry are busy summarizing the first three quarters of operation, they have also started full horsepower and sprinted to the key fourth quarter
.
Pharmaceutical equipment industry (Image source: Pharmaceutical Network) As mentioned in the research activity information released by Chutian Technology at the end of October, the company's production and operation from January to September were normal, and the overall performance was good, specifically in the following aspects: new product development, compared with last year, the company added five new product lines and dozens of new products; The growth of new orders is in line with the company's annual expectations and is confident of achieving the annual target; The construction of production capacity is steadily advancing, the construction of the fourth phase of the headquarters is about to be completed, and the new production capacity of microspheres and SUTs is steadily advancing; The layout around the biomedical industry chain has been gradually improved
.
Although ROMACO's performance in the first half of 2022 was affected by the supply chain and product delivery, Chutian Technology said in an institutional survey in September that ROMACO currently has sufficient orders in hand, and according to the situation in previous years, ROMACO's performance in the second half of the year is better than in the first half, and the whole year is confident to achieve the performance commitment
at the time of mergers and acquisitions.
According to the third quarterly report of Chutian Technology, the contract debt reached 2.
534 billion yuan, an increase of 134.
22% over the beginning of
the year.
Some analysts believe that Chutian Technology has sufficient orders in hand, which is a strong guarantee
for the company to maintain high growth in the fourth quarter and even subsequent quarters.
According to the company's business target planning for 2022, based on 2021, the net profit growth rate in 2022 will not be less than 20%, or the growth rate of operating income will not be less than 20%.

Coincidentally, Dongfulong adheres to the development strategy of "systematic, internationalized and digital intelligence" and the business goals formulated at the beginning of the year, continues to promote the diversified layout of products and the internationalization strategy, attracts talents, builds platforms, increases research and development, and ensures the steady progress of
the company's production and operation plans.
The third quarterly report of 2022 shows that Dongfulong achieved double growth in revenue and net profit during the reporting period
.
In addition, as of September 30, 2022, Dongfulong's contract liabilities reached 4.
252 billion yuan, an increase of more than
500 million yuan from 3.
731 billion yuan at the beginning of the year.
Dongfulong also mentioned on the interactive platform recently, "The company has made a large investment in personnel reserves, new product layout, and fundraising project layout from July to September, and the expenses have been greatly increased every month, which is also the foundation
for the company's future development.
" "In the first three quarters of this year, the overall performance of the pharmaceutical equipment industry was relatively good, and entering the fourth quarter, it is the norm for enterprises to seize time and seize opportunities
.
" At present, both head enterprises and small and medium-sized enterprises are accelerating production progress and making every effort to achieve the production and operation goals in the fourth quarter
.
Some industry insiders said
.
The pharmaceutical equipment industry is in the upstream position of the pharmaceutical industry and is an important part of
the pharmaceutical industry.
In recent years, with the release of favorable pharmaceutical innovation policies, more and more innovative targeted and immunotherapy drugs have been approved for marketing, promoting the continuous expansion of production capacity of biopharmaceutical companies, bringing a new round of opportunities to the pharmaceutical equipment industry, and promoting the development of the industry as a whole in the direction of providing one-stop, automation and continuity
.
At the same time, under the rapid development of the innovative drug industry, pharmaceutical outsourcing industries such as CRO and CMO/CDMO have also ushered in vigorous development, bringing more possibilities
to pharmaceutical equipment enterprises.
Under the trend of medical insurance cost control, the industry expects that the cost pressure faced by pharmaceutical companies in the future will be transmitted to the requirements for pharmaceutical equipment, forcing the pharmaceutical equipment industry to accelerate transformation and upgrading, thereby assisting pharmaceutical companies to improve process flow and reduce costs.

According to data from China Insights Consulting, it is expected that by 2025, the size of China's pharmaceutical equipment market will reach about 87.
5 billion yuan.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.